title: Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
abstract: Decitabine (DAC) is commonly used for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Previous studies have indicated DAC sequentially combined with idarubicin was an effective treatment for myeloid neoplasms. Therefore, a clinical study was conducted of the sequential combination of DAC followed by low-dose idarubicin/cytarabine in high-risk myeloid neoplasms. A total of 30 patients with a diagnosis of high-risk MDS, AML evolving from MDS or relapsed/refractory AML were enrolled in the study. DAC was administered 20 mg/m(2) daily for 3 consecutive days. Idarubicin (3 mg/m(2)/day) was administered 24 h after the last administration of DAC for 5-7 consecutive days, combined with cytarabine (30 mg/m(2)/day) for 7-14 days. The overall complete remission rate was 66.67%. The results demonstrate that epigenetic priming with decitabine followed by low-dose idarubicin/ytarabine has an increased anti-leukemia effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
authors.affiliation: a Institute of Hematology, Department of Hematology , The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China .|b MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China , and.|c Department of Hematology , The fourth Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China.
authors.forename: Xing-Nong
authors.initials: XN
authors.lastname: Ye
authors.affiliation: a Institute of Hematology, Department of Hematology , The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China .|b MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China , and.
authors.forename: Xin-Ping
authors.initials: XP
authors.lastname: Zhou
authors.affiliation: a Institute of Hematology, Department of Hematology , The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China .|b MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China , and.
authors.forename: Ju-Ying
authors.initials: JY
authors.lastname: Wei
authors.affiliation: a Institute of Hematology, Department of Hematology , The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China .
authors.forename: Gai-Xiang
authors.initials: GX
authors.lastname: Xu
authors.affiliation: a Institute of Hematology, Department of Hematology , The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China .
authors.forename: Ying
authors.initials: Y
authors.lastname: Li
authors.affiliation: a Institute of Hematology, Department of Hematology , The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China .
authors.forename: Li-Ping
authors.initials: LP
authors.lastname: Mao
authors.affiliation: a Institute of Hematology, Department of Hematology , The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China .|c Department of Hematology , The fourth Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China.
authors.forename: Jian
authors.initials: J
authors.lastname: Huang
authors.affiliation: a Institute of Hematology, Department of Hematology , The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China .|b MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China , and.
authors.forename: Yan-Ling
authors.initials: YL
authors.lastname: Ren
authors.affiliation: a Institute of Hematology, Department of Hematology , The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China .|b MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China , and.
authors.forename: Chen
authors.initials: C
authors.lastname: Mei
authors.affiliation: a Institute of Hematology, Department of Hematology , The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China .
authors.forename: Jing-Han
authors.initials: JH
authors.lastname: Wang
authors.affiliation: a Institute of Hematology, Department of Hematology , The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China .
authors.forename: Yin-Jun
authors.initials: YJ
authors.lastname: Lou
authors.affiliation: a Institute of Hematology, Department of Hematology , The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China .
authors.forename: Li-Ya
authors.initials: LY
authors.lastname: Ma
authors.affiliation: a Institute of Hematology, Department of Hematology , The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China .
authors.forename: Wen-Juan
authors.initials: WJ
authors.lastname: Yu
authors.affiliation: a Institute of Hematology, Department of Hematology , The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China .|b MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China , and.
authors.forename: Li
authors.initials: L
authors.lastname: Ye
authors.affiliation: a Institute of Hematology, Department of Hematology , The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China .|b MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China , and.
authors.forename: Li-Li
authors.initials: LL
authors.lastname: Xie
authors.affiliation: a Institute of Hematology, Department of Hematology , The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China .|b MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China , and.
authors.forename: Yin-Wan
authors.initials: YW
authors.lastname: Luo
authors.affiliation: a Institute of Hematology, Department of Hematology , The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China .|b MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China , and.
authors.forename: Chao
authors.initials: C
authors.lastname: Hu
authors.affiliation: a Institute of Hematology, Department of Hematology , The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China .|b MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China , and.
authors.forename: Lin-Mei
authors.initials: LM
authors.lastname: Niu
authors.affiliation: a Institute of Hematology, Department of Hematology , The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China .|b MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China , and.
authors.forename: Min-Hua
authors.initials: MH
authors.lastname: Dou
authors.affiliation: a Institute of Hematology, Department of Hematology , The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China .
authors.forename: Jie
authors.initials: J
authors.lastname: Jin
authors.affiliation: a Institute of Hematology, Department of Hematology , The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China .|b MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University , Hangzhou , PR China , and.
authors.forename: Hong-Yan
authors.initials: HY
authors.lastname: Tong
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001374:Azacitidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002869:Chromosome Aberrations; D003561:Cytarabine / Q000008:administration & dosage; D000077209:Decitabine; D018450:Disease Progression; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D044127:Epigenesis, Genetic / Q000187:drug effects*; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D012008:Recurrence; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D003561:Cytarabine; D000077209:Decitabine; D001374:Azacitidine; D015255:Idarubicin
keywords: Acute myeloid leukemia; cytarabine; decitabine; idarubicin; myelodysplastic syndrome